AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24051993 — intervention group
Group type: COMPARATOR
Intervention: Conventional occupational therapy alone
Number of subjects: 40
Study 22132634 — intervention group
Group type: EXPERIMENTAL
Intervention: MiniArc
Number of subjects: 66
Study 22132634 — intervention group
Group type: EXPERIMENTAL
Intervention: AJUST
Number of subjects: 66
Study 19219405 — intervention group
Group type: EXPERIMENTAL
Intervention: SC low-molecular-weight heparin (LMWH)
Number of subjects: 24
Study 19219405 — intervention group
Group type: COMPARATOR
Intervention: SC unfractionated heparin (UFH)
Number of subjects: 24
Study 16990410 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized fenofibrate for 24 months in addition to antihypertensive treatment
Number of subjects: 0
Study 16990410 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 15548851 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole fast disintegrating tablet (LFDT) with 150 mL of water
Number of subjects: 12
Study 15548851 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole fast disintegrating tablet (LFDT) without water (with saliva)
Number of subjects: 12
Study 11772907 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (up to 1,000 mg twice daily)
Number of subjects: 82
Study 11772907 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 11772907 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 82
Study 9599500 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 67
Study 9599500 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 67
Study 9599500 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 67
Study 7506223 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interferon-alpha 2a, administered in tapering doses thrice weekly for 1 year
Number of subjects: 60
Study 7506223 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group)
Number of subjects: 60
Study 7506223 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human interferon-alpha 2a
Number of subjects: 60
Study 2525870 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxazosin
Number of subjects: 130
Study 2525870 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 130
Study 31039001 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E-infused highly crosslinked polyethylene (HXLPE) insert
Number of subjects: 200
Study 31039001 — intervention group
Group type: COMPARATOR
Intervention: Conventional polyethylene insert
Number of subjects: 200
Study 31039001 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E-infused HXLPE insert
Number of subjects: 200
Study 28605291 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin and Etoposide (CE)
Number of subjects: 188
Study 28605291 — intervention group
Group type: EXPERIMENTAL
Intervention: Carboplatin, Etoposide, and Palifosfamide (PaCE)
Number of subjects: 188
Study 25136139 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient narratives (1-hour long) followed by discussion
Number of subjects: 283
Study 25136139 — intervention group
Group type: COMPARATOR
Intervention: Control teaching (conventional faculty-delivered teaching)
Number of subjects: 283
Study 23039321 — intervention group
Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg bid
Number of subjects: 449
Study 23039321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 449
Study 21819707 — intervention group
Group type: EXPERIMENTAL
Intervention: New peritoneal trocar
Number of subjects: 376
Study 21819707 — intervention group
Group type: COMPARATOR
Intervention: Conventional laparotomy
Number of subjects: 376
Study 19567647 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined radiofrequency ablation and TACE
Number of subjects: 89
Study 19567647 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation alone
Number of subjects: 89
Study 16539287 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyaluronic acid pack (Merogel)
Number of subjects: 42
Study 16539287 — intervention group
Group type: COMPARATOR
Intervention: No packing (Control)
Number of subjects: 42
Study 15499518 — intervention group
Group type: EXPERIMENTAL
Intervention: Carl Zeiss IOL-Master 99 (IOLM)
Number of subjects: 59
Study 15499518 — intervention group
Group type: EXPERIMENTAL
Intervention: Biovision Echograph Class 1 - Type B (BIOV)
Number of subjects: 59
Study 15499518 — intervention group
Group type: EXPERIMENTAL
Intervention: Allergan Humphrey Ultrasonic Biometer Mod. 820 (AHUB)
Number of subjects: 59
Study 10880059 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial factors (intrapersonal, stress-processing, social ecological)
Number of subjects: 90
Study 10880059 — intervention group
Group type: COMPARATOR
Intervention: Biomedical factors
Number of subjects: 90
Study 10880059 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychosocial factors
Number of subjects: 90
Study 8777472 — intervention group
Group type: COMPARATOR
Intervention: Carvedilol (C)
Number of subjects: 248
Study 8777472 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (E)
Number of subjects: 248
Study 1585843 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol beverage
Number of subjects: 88
Study 1585843 — intervention group
Group type: COMPARATOR
Intervention: Placebo beverage
Number of subjects: 88
Study 1585843 — intervention group
Group type: EXPERIMENTAL
Intervention: Friendly social cues
Number of subjects: 88
Study 1585843 — intervention group
Group type: COMPARATOR
Intervention: Unfriendly social cues
Number of subjects: 88
Study 1585843 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol content
Number of subjects: 88
Study 1585843 — intervention group
Group type: EXPERIMENTAL
Intervention: Amount of beverage consumed
Number of subjects: 88
Study 24049904 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy supplement with 200 mg of monensin added/kg of feed
Number of subjects: 38
Study 24049904 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein supplement with 200 mg of monensin added/kg of feed
Number of subjects: 38
Study 24049904 — intervention group
Group type: COMPARATOR
Intervention: Control group (energy supplement)
Number of subjects: 38
Study 24049904 — intervention group
Group type: COMPARATOR
Intervention: Control group (protein supplement)
Number of subjects: 38
Study 24049904 — intervention group
Group type: EXPERIMENTAL
Intervention: Monensin-treated cows (experiment I)
Number of subjects: 38
Study 24049904 — intervention group
Group type: EXPERIMENTAL
Intervention: Monensin-treated cows (experiment II)
Number of subjects: 38
Study 24049904 — intervention group
Group type: EXPERIMENTAL
Intervention: Monensin supplementation
Number of subjects: 38
Study 31431084 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of patient characteristics, trauma characteristics, and knee complaints
Number of subjects: 250
Study 31431084 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of patient characteristics, trauma characteristics, knee complaints, and MR findings
Number of subjects: 250
Study 28607125 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril and folic acid (10 mg enalapril and 0.8 mg folic acid)
Number of subjects: 13071
Study 28607125 — intervention group
Group type: COMPARATOR
Intervention: Enalapril (10 mg)
Number of subjects: 13071
Study 26009787 — intervention group
Group type: EXPERIMENTAL
Intervention: PE + NAL
Number of subjects: 159
Study 26009787 — intervention group
Group type: COMPARATOR
Intervention: PE + PBO
Number of subjects: 159
Study 26009787 — intervention group
Group type: EXPERIMENTAL
Intervention: SC + NAL
Number of subjects: 159
Study 26009787 — intervention group
Group type: COMPARATOR
Intervention: SC + PBO
Number of subjects: 159
Study 23727883 — intervention group
Group type: EXPERIMENTAL
Intervention: High-low-frequency sequence paired with leftward apparent visual motion during adaptation phase
Number of subjects: 0
Study 23727883 — intervention group
Group type: EXPERIMENTAL
Intervention: High-low-frequency sequence paired with rightward apparent visual motion during adaptation phase
Number of subjects: 0
Study 23727883 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure to audio-visual stimuli
Number of subjects: 0
Study 23727883 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to visual field
Number of subjects: 0
Study 22299414 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 2 (phone call reminder) in MDR-TB group
Number of subjects: 0
Study 22299414 — intervention group
Group type: COMPARATOR
Intervention: Model 1 (conventional DOTS) in MDR-TB group
Number of subjects: 0
Study 22299414 — intervention group
Group type: EXPERIMENTAL
Intervention: Model 2 (phone call reminder) in non-MDR-TB group
Number of subjects: 0
Study 22299414 — intervention group
Group type: COMPARATOR
Intervention: Model 1 (conventional DOTS) in non-MDR-TB group
Number of subjects: 0
Study 20035593 — intervention group
Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 284
Study 20035593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study 16982277 — intervention group
Group type: EXPERIMENTAL
Intervention: Epiphany + gutta‐percha
Number of subjects: 70
Study 16982277 — intervention group
Group type: EXPERIMENTAL
Intervention: AH Plus + gutta‐percha
Number of subjects: 70
Study 16982277 — intervention group
Group type: EXPERIMENTAL
Intervention: AH Plus + Resilon
Number of subjects: 70
Study 16982277 — intervention group
Group type: EXPERIMENTAL
Intervention: Epiphany + Resilon
Number of subjects: 70
Study 15107971 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 1.5 mg
Number of subjects: 588
Study 15107971 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus 3 mg
Number of subjects: 588
Study 15107971 — intervention group
Group type: COMPARATOR
Intervention: Mycophenolate mofetil (MMF) 2 g
Number of subjects: 588
Study 11098023 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin or doxycycline for 14 consecutive days per month for 3 months (PR: n = 40; PV: n = 20; PVE: n = 25)
Number of subjects: 122
Study 11098023 — intervention group
Group type: COMPARATOR
Intervention: No treatment (PR: n = 12; PV: n = 12; PVE: n = 13)
Number of subjects: 122
Study 11098023 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin or doxycycline
Number of subjects: 122
Study 11098023 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 122
Study 9195695 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional red cell salvage
Number of subjects: 0
Study 9195695 — intervention group
Group type: EXPERIMENTAL
Intervention: Red cell salvage with continuous processing
Number of subjects: 0
Study 9195695 — intervention group
Group type: EXPERIMENTAL
Intervention: Salvage by haemofiltration using recirculation through a 30,000‐Da filter
Number of subjects: 0
Study 9195695 — intervention group
Group type: COMPARATOR
Intervention: All three methods
Number of subjects: 0
Study 1442658 — intervention group
Group type: EXPERIMENTAL
Intervention: Guar gum (10 grams, three times a day for 6 weeks)
Number of subjects: 25
Study 3974174 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (40, 60, or 80 mg orally)
Number of subjects: 42
Study 3974174 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine (60 mg orally)
Number of subjects: 42
Study 3974174 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine i.v. (in 6 patients with vasospasm)
Number of subjects: 42
Study 3974174 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 42
Study 3544028 — intervention group
Group type: EXPERIMENTAL
Intervention: diatrizoate sodium meglumine
Number of subjects: 25
Study 3544028 — intervention group
Group type: COMPARATOR
Intervention: ioxaglate sodium meglumine
Number of subjects: 25
Study 29665087 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 1000 IU/d
Number of subjects: 305
Study 29665087 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D 400 IU/d
Number of subjects: 305
Study 29665087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305
Study 26803455 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous tibial nerve stimulation (PTNS)
Number of subjects: 41
Study 23929827 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise therapy (ET)
Number of subjects: 131
Study 23929827 — intervention group
Group type: COMPARATOR
Intervention: Exercise therapy (ET) + manual therapy (MT)
Number of subjects: 131
Study 23929827 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline predictors for ET at 9 weeks
Number of subjects: 131
Study 23929827 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline predictors for ET at 18 weeks
Number of subjects: 131
Study 23929827 — intervention group
Group type: EXPERIMENTAL
Intervention: Prognostic accuracy for predictors at 9 weeks
Number of subjects: 131
Study 24330776 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided placement of ventricular catheters using a smartphone assisted guiding tool
Number of subjects: 144
Study 24330776 — intervention group
Group type: COMPARATOR
Intervention: Standard freehand technique of ventricular catheter application
Number of subjects: 144
Study 20533796 — intervention group
Group type: EXPERIMENTAL
Intervention: Value-neutral information about genomic science (short film)
Number of subjects: 0
Study 20533796 — intervention group
Group type: COMPARATOR
Intervention: Control group (no information provided)
Number of subjects: 0
Study 18788025 — intervention group
Group type: EXPERIMENTAL
Intervention: Square puzzle session
Number of subjects: 0
Study 18788025 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% completion session
Number of subjects: 0
Study 18788025 — intervention group
Group type: EXPERIMENTAL
Intervention: Facile task trials
Number of subjects: 0
Study 18788025 — intervention group
Group type: EXPERIMENTAL
Intervention: Difficult task trials
Number of subjects: 0
Study 16845582 — intervention group
Group type: EXPERIMENTAL
Intervention: Good apology
Number of subjects: 184
Study 16845582 — intervention group
Group type: EXPERIMENTAL
Intervention: Pseudo-apology
Number of subjects: 184
Study 16845582 — intervention group
Group type: EXPERIMENTAL
Intervention: No apology
Number of subjects: 184
Study 16845582 — intervention group
Group type: COMPARATOR
Intervention: Non-harassed control
Number of subjects: 184
Study 12790293 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate (220 mg) once per day for one month
Number of subjects: 40
Study 12790293 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saccharose)
Number of subjects: 40
Study 10666180 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg per hour TFPI after a bolus of 0.0125 mg/kg (low-dose group)
Number of subjects: 16
Study 10666180 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg per hour TFPI after a bolus of 0.05 mg/kg (high-dose group)
Number of subjects: 16
Study 10666180 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 8877680 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg ranitidine (oral formulation)
Number of subjects: 16
Study 1793783 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg daily for one week
Number of subjects: 8
Study 1793783 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6571974 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen sodium (275 mg, 2 tablets at first sign of menses, followed by one tablet 4 times daily for 3 days)
Number of subjects: 12
Study 6571974 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 6571974 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen sodium
Number of subjects: 12
Study 31204597 — intervention group
Group type: EXPERIMENTAL
Intervention: Active balanced sitting chair (ST)
Number of subjects: 20
Study 31204597 — intervention group
Group type: COMPARATOR
Intervention: Stability ball (SB)
Number of subjects: 20
Study 31204597 — intervention group
Group type: COMPARATOR
Intervention: Standard chair (SC)
Number of subjects: 20
Study 30278530 — intervention group
Group type: EXPERIMENTAL
Intervention: Periocular triamcinolone acetonide (TA) injection
Number of subjects: 22
Study 30278530 — intervention group
Group type: COMPARATOR
Intervention: Anti-VEGF intravitreous injection
Number of subjects: 22
Study 25452018 — intervention group
Group type: EXPERIMENTAL
Intervention: Interspinous process devices (IPD)
Number of subjects: 159
Study 25452018 — intervention group
Group type: COMPARATOR
Intervention: Bony decompression
Number of subjects: 159
Study 24682463 — intervention group
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate at 1.4 mg/m² as 2- to 5-minute intravenous infusions on days 1 and 8 of a 21-day cycle
Number of subjects: 827
Study 22610930 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg/d)
Number of subjects: 162
Study 22610930 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (1000 mg/d)
Number of subjects: 162
Study 22610930 — intervention group
Group type: COMPARATOR
Intervention: Placebo matching doxycycline
Number of subjects: 162
Study 22610930 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline and Amoxicillin
Number of subjects: 162
Study 20562608 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (600 mg prior to surgery, and 75 mg daily for 3 days; n = 50)
Number of subjects: 108
Study 20562608 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 58)
Number of subjects: 108
Study 20562608 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 108
Study 18626047 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fluconazole, 800 mg daily for 2 weeks
Number of subjects: 270
Study 18626047 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 2 weeks
Number of subjects: 270
Study 18626047 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous fluconazole, 800 mg daily
Number of subjects: 270
Study 18626047 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 270
Study 16003538 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month resistance training (TRN), training three times a week
Number of subjects: 13
Study 16003538 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-month resistance training (TRN)
Number of subjects: 13
Study 16003538 — intervention group
Group type: COMPARATOR
Intervention: Control group (CTRL)
Number of subjects: 13
Study 11115415 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine test (Phe-BRS)
Number of subjects: 104
Study 11115415 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva manoeuvre (Ov-VM-BRS)
Number of subjects: 104
Study 11115415 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva manoeuvre (IV-VM-BRS)
Number of subjects: 104
Study 11115415 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotomized Ov-VM-BRS
Number of subjects: 104
Study 9863081 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuefuzhuyu Pill (XFZYP)
Number of subjects: 12
Study 9863081 — intervention group
Group type: COMPARATOR
Intervention: Aspirin
Number of subjects: 12
Study 8145982 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% levobunolol
Number of subjects: 59
Study 8145982 — intervention group
Group type: COMPARATOR
Intervention: 2% carteolol
Number of subjects: 59
Study 2462025 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved field irradiation (IF) plus six cycles of vinblastine, bleomycin, and methotrexate (VBM)
Number of subjects: 67
Study 2462025 — intervention group
Group type: COMPARATOR
Intervention: Subtotal or total lymphoid irradiation (STLI/TLI) alone
Number of subjects: 67
Study 2462025 — intervention group
Group type: COMPARATOR
Intervention: Involved field irradiation (IF) alone (previous results)
Number of subjects: 67
Study 2462025 — intervention group
Group type: COMPARATOR
Intervention: Involved field irradiation (IF) plus nitrogen mustard, vincristine, procarbazine, +/‐ prednisone (MOP[P]) chemotherapy (previous results)
Number of subjects: 67
Study 30991110 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives for weight management programs (Healthy Choices Healthy Changes: HCHC)
Number of subjects: 2009
Study 30991110 — intervention group
Group type: EXPERIMENTAL
Intervention: Financial incentives for smoking cessation interventions (Breathe Well Live Well: BWLW)
Number of subjects: 2009
Study 30991110 — intervention group
Group type: COMPARATOR
Intervention: No financial incentives for weight management programs (Healthy Choices Healthy Changes: HCHC)
Number of subjects: 2009
Study 30991110 — intervention group
Group type: COMPARATOR
Intervention: No financial incentives for smoking cessation interventions (Breathe Well Live Well: BWLW)
Number of subjects: 2009
Study 28424897 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic Case History Tool (e‐HiT)
Number of subjects: 40
Study 28424897 — intervention group
Group type: COMPARATOR
Intervention: Paper-based version (PBV)
Number of subjects: 40
Study 25751133 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastat activated after 4 weeks (Group 1)
Number of subjects: 30
Study 25751133 — intervention group
Group type: COMPARATOR
Intervention: Diastat activated after 12 weeks (Group 2)
Number of subjects: 30
Study 24082784 — intervention group
Group type: EXPERIMENTAL
Intervention: mIoT management
Number of subjects: 600
Study 24082784 — intervention group
Group type: COMPARATOR
Intervention: Routine follow-up
Number of subjects: 600
Study 21390262 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling (three counseling sessions around HAART initiation)
Number of subjects: 400
Study 21390262 — intervention group
Group type: COMPARATOR
Intervention: Alarm (pocket electronic pill reminder carried for 6 months)
Number of subjects: 400
Study 21390262 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling plus alarm
Number of subjects: 400
Study 21390262 — intervention group
Group type: COMPARATOR
Intervention: Neither counseling nor alarm
Number of subjects: 400
Study 19395227 — intervention group
Group type: EXPERIMENTAL
Intervention: Caregivers with limited health literacy
Number of subjects: 110
Study 19395227 — intervention group
Group type: COMPARATOR
Intervention: Caregivers with adequate health literacy
Number of subjects: 110
Study 17669080 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed Loop Stimulation (CLS) pacing mode
Number of subjects: 0
Study 17669080 — intervention group
Group type: COMPARATOR
Intervention: Accelerometer pacing mode
Number of subjects: 0
Study 15509084 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitening toothpaste (natural calcium carbonate/perlite)
Number of subjects: 600